10-K: Humacyte Launches Symvess, Faces Going Concern Doubt

Humacyte, Inc. commenced U.S. commercial sales of its FDA-approved Symvess for vascular trauma in Q1 2025, generating $1.4 million in revenue, but faces substantial doubt about its ability to continue as a going concern.

Summary

• Commenced the U.S. commercial launch of Symvess for extremity vascular injury in the first quarter of 2025, following full FDA approval on December 19, 2024.
• Generated $1.4 million in product revenue for the year ended December 31, 2025, marking the company's first commercial sales.
• Reported a net loss of $40.8 million for the year ended December 31, 2025, a significant reduction from $148.7 million in 2024, primarily due to non-cash gains from fair value remeasurements.
• Operating losses were $108.1 million in 2025, compared to $114.4 million in 2024.
• Cash and cash equivalents stood at $50.5 million as of December 31, 2025.
• Substantial doubt exists about the company's ability to continue as a going concern beyond one year without generating sufficient cash flows from commercial sales or obtaining additional capital.
• Positive topline results from the V007 Phase 3 trial for AV access in hemodialysis were reported in August 2024, meeting co-primary endpoints.
• Two-year results from the V007 trial, presented in November 2025, showed superior duration of access for ATEV in female, obese, and diabetic patients compared to AV fistula.
• An ongoing V012 Phase 3 trial is assessing ATEV for AV access in hemodialysis in women, with interim analysis expected in Q2 2026.
• Plans to submit a supplemental Biologics License Application (BLA) for ATEV for AV access for hemodialysis in the second half of 2026, targeting high-risk patient subgroups.
• Preclinical results for the coronary tissue engineered vessel (CTEV) in a baboon model for coronary artery bypass grafting (CABG) were published in September 2025, demonstrating sustained patency, recellularization, and adaptive remodeling.
• Preclinical study results for CTEV as a modified Blalock-Taussig-Thomas (mBTT) shunt in pediatric heart surgery were published in October 2023, showing patency, structure, and blood flow.
• Secured a $77.5 million senior secured term loan facility in December 2025, with an initial $40.0 million funded to repay previous debt obligations.
• Completed a registered direct offering on March 20, 2026, raising approximately $18.4 million in net proceeds.
• Received a minimum purchase commitment of approximately $1.48 million for Symvess in the Kingdom of Saudi Arabia, with ongoing negotiations for a joint venture and license.
• Filed a Marketing Authorization Application (MAA) for Symvess in the vascular trauma indication with the Ministry of Health of the State of Israel on March 16, 2026.
• Implemented a workforce reduction of 30 employees in April 2025 as part of cost-saving measures.
• Multiple ongoing legal proceedings, including a putative securities class action lawsuit and several stockholder derivative actions, allege false or misleading statements and breaches of fiduciary duty.

Sentiment

Score: 4

Explanation: StockSavvy.ai views this as a mixed filing. While the FDA approval of Symvess and initial commercial sales are positive milestones, the significant ongoing losses, going concern doubt, and legal challenges present considerable financial and operational headwinds. The strong clinical data in specific subgroups for AV access and promising preclinical results are encouraging, but the V006 trial's failure to meet its primary endpoint and the Symvess boxed warning temper enthusiasm.

Positives

• FDA granted full approval for Symvess for extremity arterial injury on December 19, 2024, and commercial launch commenced in Q1 2025.
• Generated $1.4 million in product revenue in 2025, marking the company's first commercial sales.
• Positive topline results from the V007 Phase 3 trial for AV access in hemodialysis, meeting co-primary endpoints (functional patency at 6 months: 81.3% ATEV vs 66.4% AVF; secondary patency at 12 months: 68.3% ATEV vs 62.2% AVF).
• V007 trial showed superior duration of access for ATEV in female, obese, and diabetic patients over 24 months (15.8 months for ATEV vs 10.0 months for AVF in females; 14.8 months for ATEV vs 9.1 months for AVF in target population).
• ATEV demonstrated significantly lower infection rates compared to ePTFE grafts in the V006 trial (0.93% ATEV/yr vs 4.5% ePTFE/yr).
• Combined V005 and V017 (Ukraine humanitarian program) trials for vascular trauma showed strong 30-day secondary patency (91.5%), low conduit infection rate (0.9%), and low amputation rate (4.5%) compared to synthetic graft benchmarks.
• A Budget Impact Model published in March 2025 projected Symvess to be cost-saving for trauma centers and third-party payors due to reductions in amputations and infections.
• Received Regenerative Medicine Advanced Therapy (RMAT) designation for ATEV for urgent arterial repair following extremity vascular trauma (May 2023) and for advanced Peripheral Artery Disease (PAD) (June 2024).
• Received Fast Track designation for 6mm ATEV for AV access in hemodialysis (2014) and first RMAT designation for vascular access for hemodialysis (March 2017).
• The Department of Defense (DoD) assigned priority designation to ATEV technology under Public Law 115-92 and provided an approximately $6.8 million grant for vascular reconstruction and repair.
• Preclinical studies for BioVascular Pancreas (BVP) in primates showed insulin-producing cells survive for months and produce measurable insulin.
• Preclinical results for CTEV in CABG (baboon model) published in September 2025 showed sustained patency, recellularization, and adaptive remodeling.
• Preclinical study for CTEV as mBTT shunt in pediatric heart surgery published in October 2023 showed patency, structure, and blood flow.
• Secured a $77.5 million senior secured term loan facility in December 2025, providing capital and repaying previous debt.
• Successfully completed a registered direct offering in March 2026, raising $18.4 million net.
• Received a minimum purchase commitment of $1.48 million for Symvess in Saudi Arabia, indicating international interest.
• Filed MAA for Symvess in vascular trauma in Israel, expanding international regulatory efforts.
• No instances of clinical rejection of ATEV observed in any clinical trial over ten years.
• ATEVs remodel with host cells after implantation, transforming into living tissue capable of self-healing.

Negatives

• Incurred significant operating losses ($108.1 million in 2025) and negative cash flows from operations ($105.0 million in 2025) since inception.
• Accumulated deficit of $726.8 million as of December 31, 2025.
• Substantial doubt exists about the company's ability to continue as a going concern beyond one year without additional capital or sufficient commercial sales.
• The Symvess package insert contains a boxed warning relating to mid-graft rupture or anastomotic failure, and a post-approval long-term observational study is required.
• The V006 trial for AV access did not meet its primary efficacy endpoint regarding secondary patency compared to ePTFE, which was an unexpected outcome.
• The proposed CABG clinical trial is on a clinical hold until batch testing data for the smaller diameter ATEV can be provided to the FDA.
• Reliance on sole-source suppliers for critical components (SeraCare for human plasma, Confluent for polymer mesh).
• Multiple ongoing legal proceedings (securities class action, derivative actions) alleging false or misleading statements, breach of fiduciary duty, and other claims, with potential for material loss.
• Workforce reduction of 30 employees in April 2025, indicating cost pressures.
• Suspended and terminated the ATM Prospectus for the TD Cowen ATM Facility on March 19, 2026, limiting a potential source of capital.
• The company has limited experience manufacturing commercial product and may encounter difficulties in scaling production.
• The Loan Agreement limits the ability to incur future debt without consent, potentially restricting financial flexibility.
• The company does not anticipate paying any cash dividends in the foreseeable future.

Risks

• Incurred significant losses to date and expects to continue incurring losses, may never generate significant product revenue or be profitable, and will need to raise additional capital which may not be available on acceptable terms or at all.
• Near-term prospects depend on Symvess sales in vascular trauma and obtaining regulatory approval for additional indications; failure to increase sales or obtain approvals would materially harm the business.
• Symvess and product candidates may fail to achieve market acceptance by physicians, patients, third-party payors, and others.
• Risk of enforcement action, civil liability, regulatory investigation, and penalties for improper off-label promotion.
• Substantial competition from existing treatments (autologous veins, synthetic grafts, allografts, xenografts) and emerging technologies.
• Clinical trials may fail to demonstrate safety and efficacy, leading to additional costs, delays, or inability to complete development and commercialization.
• Delays or difficulties in patient enrollment in clinical trials.
• Lack of experience by investigators and surgeons with ATEVs could lead to incorrect implantation or follow-up procedures, harming clinical trial results and market acceptance.
• Inability to successfully use proprietary scientific technology platform to build a pipeline of additional product candidates.
• Market opportunity estimates for Symvess and product candidates may be inaccurate or approvals may be based on narrower patient populations.
• Distribution agreement with Fresenius Medical Care imposes obligations that may restrict business operations.
• Inability to establish own marketing, sales, and distribution capabilities for products not covered by the Fresenius agreement.
• Complexity of manufacturing Symvess and product candidates, limited commercial manufacturing experience, and potential for batch failures or production difficulties.
• Terms of the Loan Agreement may limit ability to incur future debt.
• Reliance on third parties to conduct and support clinical trials, with risks of unsatisfactory performance or non-adherence to requirements.
• Reliance on sole-source suppliers for critical components, with risks of supply failure or delays.
• Disruption of the strategic partnership with Fresenius Medical Care.
• Inability to obtain and maintain effective intellectual property rights or challenges to existing patents.
• Potential for write-downs, write-offs, restructuring, or impairment charges.
• Serious Adverse Events (SAEs) occurring at unacceptable rates or unexpected side effects could delay, abandon, or limit development and marketing.
• Interim, topline, and preliminary data from clinical trials may change.
• Ongoing regulatory obligations and review, including post-approval studies and potential penalties for non-compliance.
• Product recalls could harm reputation and business.
• Failure to obtain marketing approval from the FDA for product candidates.
• Lengthier and more expensive review periods for novel product candidates.
• Inability to obtain or maintain orphan drug designation benefits.
• Inadequate funding for FDA and other government agencies.
• Delays or rejections due to future legislation or changes in regulatory policy.
• Healthcare reform measures (e.g., Inflation Reduction Act, most-favored-nation pricing) could hinder commercial success and reimbursement.
• Failure to comply with healthcare regulations (Anti-Kickback, False Claims, HIPAA, Sunshine Act) could lead to substantial penalties.
• Risks associated with consignment inventory arrangements (viability, accounting, tax).
• Business disruption from system failures, security breaches, data loss, or violations of data protection laws.
• Natural disasters could adversely affect operations.
• Failure to comply with anti-corruption and other international laws.
• Inability to protect confidentiality of trade secrets.
• Third parties asserting intellectual property infringement claims.
• Failure to comply with intellectual property license obligations.
• Inability to obtain necessary intellectual property rights for pipeline candidates through acquisitions/in-licenses.
• Patent terms may be inadequate.
• Inability to protect intellectual property rights globally.
• U.S. Government grants and contracts trigger obligations (march-in rights, reporting, U.S.-based manufacturing preference).
• Inadequate protection of trademarks and trade names.
• Dependence on key employees and ability to attract/retain qualified personnel.
• Difficulties in managing workforce growth.
• Volatility of common stock price.
• Reports by analysts differing from actual results could affect stock price.
• Issuance of additional shares could dilute ownership and depress market price.
• No anticipated cash dividends.
• Public Warrants may expire worthless or be amended adversely.
• Redemption of unexpired Public Warrants at a disadvantageous time.
• Derivative securities accounted for as assets/liabilities can cause financial results to fluctuate.
• Inflation could adversely impact business.
• Legal and other proceedings could cause significant expenses and divert management attention.
• Changes in U.S. government policies (tariffs, research funding) could adversely affect business.
• Write-downs, write-offs, restructuring, or impairment charges could negatively affect financial condition and stock price.

Future Outlook

The company expects to continue incurring substantial operating losses and negative cash flows from operations for the foreseeable future as it scales the commercialization of Symvess and advances its product candidates. It plans to submit a supplemental BLA for ATEV for AV access for hemodialysis in the second half of 2026, contingent on interim V012 trial results, and to commence first human clinical testing of CTEV in CABG in the second half of 2026, pending IND clearance. The company intends to introduce a 13cm-long ATEV line extension and will continue to explore broader applications of its technology, including urinary conduit, trachea, esophagus, and novel cell delivery systems. Workforce expansion is anticipated in development, regulatory affairs, manufacturing, sales, marketing, quality, and compliance. Future funding requirements will depend on the progress and costs of these activities, with plans to seek additional capital through various financing and collaboration arrangements.

Management Comments

• "The Company will not have sufficient liquidity to fund its operations beyond one year from the issuance of these financial statements if the Company is unable to generate sufficient cash flows from commercial sales on a timely basis and/or obtain additional capital."
• "The Company plans to seek additional funding through private or public equity financings, debt financings, debt refinancings or restructurings, collaborations, strategic alliances, and marketing, distribution or licensing arrangements."
• "If the Company is unable to raise capital, the Company plans to implement a program that delays, reduces, suspends or ceases certain of its planned capital expenditures, research and development programs or any future commercialization efforts, which would have a negative impact on its business, prospects, operating results and financial condition."
• "We believe our regenerative medicine technology has the potential to overcome limitations in existing standards of care and address the lack of significant innovation in products that support tissue repair, reconstruction and replacement."
• "Given the competitive advantages our ATEVs are designed to have over existing vascular substitutes, we believe that ATEVs have the potential to become the standard of care and lead to improved patient outcomes and lower healthcare costs."
• "We believe our established, controlled manufacturing process demonstrates a significant competitive advantage in the regenerative medicine market."

Industry Context

StockSavvy.ai notes that Humacyte operates in the highly competitive and rapidly evolving biotechnology and regenerative medicine sector, targeting significant unmet needs in vascular repair and replacement. The company's focus on universally implantable, bioengineered human tissues positions it against traditional treatments like autologous veins and synthetic grafts, which have known limitations such as infection risk and harvesting morbidity. The FDA's RMAT and Fast Track designations highlight the innovative nature and potential of Humacyte's ATEV technology in addressing serious or life-threatening conditions, aligning with broader industry trends towards advanced therapies. The strategic partnership with Fresenius Medical Care for international distribution underscores the importance of established channels in specialized markets, a common strategy for biotech firms entering commercialization. The legal challenges faced by Humacyte, including securities litigation, are not uncommon for companies in this high-stakes industry, particularly those transitioning from R&D to commercial stages.

Comparison to Industry Standards

• **Vascular Trauma (Symvess vs. Synthetic Grafts):** Combined V005/V017 ATEV 30-day secondary patency was 91.5% compared to a Synthetic Graft Benchmark of 78.9%. The ATEV conduit infection rate was 0.9% versus 8.4% for synthetic grafts, and the amputation rate was 4.5% versus 24.3% for synthetic grafts.
• **AV Access for Hemodialysis (ATEV vs. AV Fistula):** In the V007 Phase 3 trial, ATEV showed superior 6-month functional patency (81.3% vs. 66.4%, p=0.0071) and 12-month secondary patency (68.3% vs. 62.2%) compared to autogenous AV fistula (AVF) for all patients. For female patients, ATEV demonstrated significantly higher 6-month functional patency (89.2% vs. 54.5%, p<0.0001) and 12-month secondary patency (81.1% vs. 48.5%). In the target population (females and males with obesity and diabetes), ATEV showed 6-month functional patency of 85.7% vs. 51.9% for AVF (p<0.0001) and 12-month secondary patency of 76.8% vs. 46.3%.
• **AV Access for Hemodialysis (ATEV vs. ePTFE):** The V006 Phase 3 trial showed ATEV had a statistically significant lower rate of conduit infections (0.93% ATEV/yr vs. 4.5% ePTFE/yr) but did not meet its primary efficacy endpoint for non-inferiority in secondary patency at 24 months (67% ATEV vs. 74% ePTFE).
• **Peripheral Artery Disease (ATEV vs. Published Literature):** The V004 trial reported zero amputations for Rutherford stage 4 and 5 patients with no autologous vein available, which compares favorably to published amputation rates of 31% at 6 months for no revascularization and approximately 10% at one year for saphenous vein revascularization. A Mayo Clinic study in CLTI patients (without available vein) showed an 86% limb salvage rate (14% amputation) at a median of nine months, compared to a 30-50% one-year amputation risk for this patient group without revascularization.

Management Changes

Corporate Governance

Legal Proceedings

• **Securities Litigation (Cutshall v. Humacyte, Inc., et al.):** A putative class action lawsuit filed November 18, 2024, and amended May 22, 2025, alleging false or misleading statements and omissions related to Symvess safety, manufacturing facility deficiencies, and financial condition/liquidity. The class period is August 14, 2023, to March 25, 2025. Defendants moved to dismiss on July 25, 2025, with the court's ruling pending.
• **Consolidated Derivative Action (Silva v. Sebelius, et al. and Misko v. Niklason, et al.):** Two stockholder derivative actions filed January 7 and 10, 2025, consolidated February 18, 2025. These actions allege violations of Section 14(a) of the Exchange Act, breach of fiduciary duty, unjust enrichment, abuse of control, gross mismanagement, and waste of corporate assets. The actions are stayed pending final resolution of the Securities Litigation.
• **Olson Action (Olson v. Niklason, et al.):** A stockholder derivative action filed February 19, 2025, following a demand letter on December 19, 2024. The complaint asserts claims substantially similar to those in the Consolidated Derivative Action and is stayed pending final resolution of the Securities Litigation.
• **2025 Demand Letter:** Received May 19, 2025, with demands and allegations similar to the 2024 Demand Letter. The Board deferred action on this demand pending the resolution of the motion to dismiss in the Securities Litigation.
• **Dusci Action (Dusci v. Bamforth, et al.):** A putative stockholder derivative action filed June 9, 2025, in Delaware, asserting claims substantially similar to the other derivative actions. This action is also stayed pending final resolution of the Securities Litigation.
• The Company disputes all claims in these lawsuits and is currently unable to estimate the potential loss or range of loss, if any, but states it could be material. No material liabilities have been accrued as a negative outcome is deemed not probable as of December 31, 2025.

Related Party Transactions

• **Fresenius Medical Care:** Holds 15,812,735 shares of Common Stock from a 2018 financing and an additional 2.5 million shares from a 2021 PIPE Financing. Has an exclusive distribution agreement (amended Feb 16, 2021) for the 6mm x 42cm ATEV outside the U.S. and EU, and collaborates on U.S. commercialization. Humacyte is obligated to pay Fresenius Medical Care a low double-digit percentage of U.S. net sales, decreasing to mid-single digits after a certain total amount. Fresenius Medical Care pays Humacyte for ex-U.S. sales based on manufacturing cost plus a fixed amount, then a fixed percentage of net sales (>50%). $0.2 million in royalties were payable to Fresenius Medical Care as of December 31, 2025.
• **Frenova Renal Research (subsidiary of Fresenius Medical Care):** Engaged to provide clinical research services for the V012 Phase 3 clinical trial. $0.3 million expense recognized in 2025.
• **Fresenius Medical Care Deutschland GmbH (parent of Fresenius GmbH, ultimately Fresenius Medical Care):** Entered into a service agreement in July 2024 to conduct a study reviewing patient data of hemodialysis patients in Europe through Frenova. No expense recognized in 2025, $0.1 million in 2024.
• **Yale University:** The company has license agreements with Yale for patents related to the BioVascular Pancreas (BVP License Agreement) and tubular prostheses (Tubular Prosthesis License Agreement). These agreements involve annual maintenance fees (up to <$0.1 million/year), milestone payments ($0.2 million and $0.6 million), low single-digit percentage royalties on worldwide net sales, and low double-digit percentage of sublicensing income. Dr. Laura Niklason, President and CEO, serves as an Adjunct Professor at Yale. Approximately $0.1 million expense was recognized in 2025 and 2024 related to these agreements.
• **JDRF (Breakthrough T1D):** Entered into an Industry Discovery and Development Partnership Agreement on April 1, 2023, to develop the BVP product candidate. JDRF provides funding up to $0.9 million based on milestones. Humacyte has agreed to pay JDRF a one-time royalty (four times the Actual Award) in three installments after the first commercial sale, an additional royalty after net sales exceed $250 million, and a Disposition Payment (10% of license/purchase price payments up to a Royalty Cap) in certain transaction events. Received $495 thousand from JDRF as of December 31, 2025. $0.1 million interest expense related to the JDRF liability was recorded in 2025 and 2024.

Stakeholder Impact

• **Shareholders:** Face potential dilution from recent and future equity raises, stock price volatility, and no anticipated dividends. The ongoing legal proceedings and the 'going concern' doubt introduce significant investment risk.
• **Patients:** Benefit from the availability of Symvess for vascular trauma, with potential for improved outcomes and lower healthcare costs. Future product candidates aim to address unmet needs in AV access for hemodialysis (especially high-risk groups), PAD, CABG, pediatric heart defects, and Type 1 diabetes. However, the boxed warning on Symvess for mid-graft rupture/anastomotic failure is a safety concern.
• **Employees:** Experienced a workforce reduction in April 2025, and future employment stability may be impacted by the company's ability to secure additional capital and achieve profitability. Competition for qualified personnel is noted.
• **Customers (Hospitals/Surgeons):** Gain access to an off-the-shelf, non-immunogenic, low-infection vascular conduit (Symvess) that can potentially reduce surgical time and complications. The Budget Impact Model suggests cost savings for trauma centers.
• **Suppliers:** The company's reliance on sole-source suppliers for critical components creates supply chain risk for both the company and its suppliers.
• **Creditors (Avenue Venture Opportunities Fund II, L.P.):** The Term Loan Facility is secured by substantially all company assets and includes covenants and potential for accelerated repayment upon default, providing some protection but also exposing them to the company's financial health.

Next Steps

• Report top-line interim results from the V012 Phase 3 trial in Q2 2026.
• Submit a supplemental BLA for ATEV for AV access for hemodialysis in H2 2026, targeting high-risk subgroups.
• Commence first human clinical testing of CTEV in CABG in H2 2026, dependent on IND clearance.
• Introduce a 13cm-long ATEV line extension after the commercial launch of the 42cm ATEV for vascular trauma.
• Continue to explore the application of technology across a broad range of markets and indications (urinary conduit, trachea, esophagus, novel cell delivery systems).
• Expand manufacturing capacity to over 40 LUNA200 systems as needed to satisfy market demand.
• Continue to develop redundant vendors for all critical materials.
• Conduct a post-approval long-term observational study for Symvess to further characterize risks of graft failure and infection.
• Conduct an open-label study to assess the safety and efficacy of Symvess in patients 17 years of age or younger.
• Negotiate for establishment of a joint venture and license to commercialize Symvess in Saudi Arabia.
• Pursue methods of making Symvess available on a hospital-by-hospital basis in Israel in advance of MAA approval.
• Perform a Section 382 study when forthcoming profitability is reasonably anticipated to assess net operating loss carryforward limitations.

Key Dates

Recommendation

Humacyte presents a high-risk, high-reward profile. The FDA approval of Symvess and initial commercial sales are significant achievements, and the positive clinical data for AV access in high-risk patient populations and promising preclinical pipeline offer substantial long-term potential. However, the explicit "going concern" warning, ongoing significant operating losses, and the boxed warning on Symvess introduce considerable near-term financial and operational uncertainty. The multiple legal proceedings also add a layer of unpredictable risk. While the recent capital raises provide some liquidity, the company's long-term viability hinges on successful commercialization and further capital, which remains uncertain. A seasoned investor would likely hold, awaiting clearer signs of sustainable revenue generation and resolution of the going concern and legal issues, while monitoring the progress of the pipeline.

Keywords

Biotechnology, Regenerative Medicine, Bioengineered Tissues, ATEV, Symvess, Vascular Trauma, Hemodialysis Access, Peripheral Artery Disease, PAD, CABG, Pediatric Heart Surgery, Type 1 Diabetes, BioVascular Pancreas, FDA Approval, Clinical Trials, Medical Devices, Biologics, 10-K, Humacyte